NN 344

Drug Profile

NN 344

Alternative Names: NN344

Latest Information Update: 16 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jan 2008 Discontinued - Phase-I for Type-1 diabetes mellitus in Denmark (SC)
  • 16 Jan 2008 Discontinued - Phase-I for Type-2 diabetes mellitus in Denmark (SC)
  • 12 Jan 2006 Changed indication Diabetes mellitus to Type-1 and Type-2 diabetes mellitus as per Novo Nordisk's R&D Pipeline (Website, 11/01/2006)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top